SRPT

Sarepta Therapeutics Inc

Add to Watchlist

Advanced Chart

17.940

-0.29(-1.591%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

19.250

Open

17.410

VWAP

18.11

Vol

11.12M

Mkt Cap

1.75B

Low

17.280

Amount

201.36M

EV/EBITDA(TTM)

41.66

Total Shares

97.71M

2.09B

EV/OCF(TTM)

P/S(TTM)

0.79

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

386.46M

-48.12%

328.97M

-50.04%

341.63M

-26.87%

Estimates Revision

The market is revising Downward the revenue expectations for Sarepta Therapeutics, Inc. (SRPT) for FY2025, with the revenue forecasts being adjusted by -18.24% over the past three months. During the same period, the stock price has changed by -50.67%.

Revenue Estimates for FY2025

Revise Downward

-18.24%

In Past 3 Month

Stock Price

Go Down

-50.67%

In Past 3 Month

29 Analyst Rating

25.08% Upside

Wall Street analysts forecast SRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 22.44 USD with a low forecast of 5.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

19 Hold

5 Sell

Hold

25.08% Upside

Current: 17.940

Low

5.00

Averages

22.44

High

80.00

25.08% Upside

Current: 17.940

Low

5.00

Averages

22.44

High

80.00

Citi

Sell

maintain

$12 -> $14

2025-08-10

New

Reason

Citi

Price Target

$12 -> $14

2025-08-10

New

maintain

Sell

Reason

Citi raised the firm's price target on Sarepta to $14 from $12 and keeps a Sell rating on the shares. The company's Q2 sales beat estimates on a Roche milestone payment for the Japanese Elevidys approval, gains on strategic investments, and an income tax benefit, the analyst tells investors in a research note. Citi continues to see risk to the shares from the Elevidys liver-toxicity overhang, which it believes is not going away.

Wells Fargo

Overweight

maintain

$48 -> $50

2025-08-07

New

Reason

Wells Fargo

Price Target

$48 -> $50

2025-08-07

New

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Sarepta to $50 from $48 and keeps an Overweight rating on the shares. Following a few eventful weeks and the preannounced quarterly results, the firm reiterates its confidence in the ELEVIDYS franchise given what Wells sees as an intact benefit-risk for ambulatory patients and potential upside from future updates on the non- ambulatory side.

JPMorgan

Underweight -> Neutral

upgrade

$24

2025-07-29

Reason

JPMorgan

Price Target

$24

2025-07-29

upgrade

Underweight -> Neutral

Reason

JPMorgan upgraded Sarepta to Neutral from Underweight with a $24 price target. The FDA's recommendation to remove the voluntary pause of shipments of Elevidys in ambulatory patients is a "clear win" for the company, the analyst tells investors in a research note. The firm points out the recommendation comes without the need for additional clinical trial work. However, JPMorgan believes understanding the Elevidys launch following this "unprecedented regulatory situation" could take a couple quarters. It worries about further "headline risk."

Oppenheimer

Andreas Argyrides

Perform

Outperform

upgrade

$30 -> $37

2025-07-29

Reason

Oppenheimer

Andreas Argyrides

Price Target

$30 -> $37

2025-07-29

upgrade

Perform

Outperform

Reason

Oppenheimer analyst Andreas Argyrides upgraded Sarepta to Outperform from Perform with a price target of $37, up from $30, after the FDA recommended to remove the voluntary hold of Elevidys for ambulatory patients. The firm believes the news is the desired outcome for the Duchenne muscular dystrophy community and provides additional comfort that the gene therapy's risk-benefit profile remains favorable in ambulatory patients. Opco cites the removal of the regulatory overhang and Elevidys being back on the market for the upgrade.

Bernstein

Market Perform

initiated

$13

2025-07-29

Reason

Bernstein

Price Target

$13

2025-07-29

initiated

Market Perform

Reason

Bernstein initiated coverage of Sarepta with a Market Perform rating and $13 price target. The firm models Elevidys \"as a zero going forward\" and tells investors to do the same. The analyst is skeptical that a \"short\" 10-12 patient study would be sufficient for the FDA, despite a recent statement from an unnamed FDA official to that effect. Bernstein believes \"it is only a matter of time before we learn of a death in an ambulatory patient that is deemed to be Elevidys-related.\"

H.C. Wainwright

Sell

maintain

$0 -> $5

2025-07-29

Reason

H.C. Wainwright

Price Target

$0 -> $5

2025-07-29

maintain

Sell

Reason

H.C. Wainwright raised the firm's price target on Sarepta to $5 from 0c and keeps a Sell rating on the shares after the FDA recommended removal of the voluntary hold for Elevidys in ambulatory Duchenne muscular dystrophy patients in the U.S. The firm says Sarepta's "existential crisis" is averted, "for now." It calls the shares rallying above $20 on the news "irrational exuberance."

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sarepta Therapeutics Inc (SRPT.O) is -23.23, compared to its 5-year average forward P/E of -0.19. For a more detailed relative valuation and DCF analysis to assess Sarepta Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.19

Current PE

-23.23

Overvalued PE

32.14

Undervalued PE

-32.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.57

Current EV/EBITDA

13.97

Overvalued EV/EBITDA

84.71

Undervalued EV/EBITDA

-85.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

7.85

Current PS

1.22

Overvalued PS

11.81

Undervalued PS

3.88

Financials

Annual

Quarterly

FY2025Q2

YoY :

+68.38%

611.09M

Total Revenue

FY2025Q2

YoY :

-16587.45%

115.58M

Operating Profit

FY2025Q2

YoY :

+2947.86%

196.89M

Net Income after Tax

FY2025Q2

YoY :

+2600.00%

1.89

EPS - Diluted

FY2025Q2

YoY :

-1712.32%

229.35M

Free Cash Flow

FY2025Q2

YoY :

-14.42%

74.93

Gross Profit Margin - %

FY2025Q2

YoY :

+1710.11%

32.22

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

248.2K

USD

6-9

Months

1.5M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 12693.27% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

703.6K

Volume

6-9

Months

5.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.6M

Volume

Months

6-9

2.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

8.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

248.2K

USD

6-9

Months

1.5M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SRPT News & Events

Events Timeline

2025-08-11 (ET)

2025-08-11

09:01:23

Video: Nvidia, AMD said to pay U.S. 15% of revenue from China chip sales

2025-08-09 (ET)

2025-08-09

13:28:34

Vinay Prasad returns to FDA as head of CBER

2025-08-06 (ET)

2025-08-06

17:18:23

Sarepta reports Q2 adjusted EPS $2.02, consensus $1.16

News

9.0

08-11Globenewswire

PinnedSarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

5.0

08-11Reuters

Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency

5.0

08-11Barron's

Prasad’s FDA Return Adds to Leadership Turmoil at U.S. Health Agencies